Atossa Therapeutics (ATOS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Atossa Therapeutics (ATOS) is Moderate Underperform.

The composite score behind that read is -0.39, weighing +0.21 of bullish evidence against -0.40 bearish.

Atossa Therapeutics last closed at $2.45, +4.70% on the session.

Against the IVW growth benchmark the position is +3.78% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

16 graded predictions for ATOS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Atossa Therapeutics in the 10th percentile on return on equity, where 100 is best.

Atossa Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $23.35M.

StockMap tracks Atossa Therapeutics as the 300th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Atossa Therapeutics ranks 297th of 344 in the group, against a group median of -0.21.